Paper35565286
Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma.
Blanco M and 4 others. Cancers (Basel), 2022. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma. Papers, record 35565286. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35565286
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References80
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21785430 | Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. | Nat Med | 2011 | https://conductscience.org/library/papers/21785430 | PubMed |
| 2 | 31112476 | Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/31112476 | PubMed |
| 3 | 24617454 | A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. | Br J Haematol | 2014 | https://conductscience.org/library/papers/24617454 | PubMed |
| 4 | 30742566 | DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/30742566 | PubMed |
| 5 | 32540726 | Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis. | Int Immunopharmacol | 2020 | https://conductscience.org/library/papers/32540726 | PubMed |
| 6 | 1956400 | Intraclonal generation of antibody mutants in germinal centres. | Nature | 1991 | https://conductscience.org/library/papers/1956400 | PubMed |
| 7 | 24332512 | Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. | Lancet Oncol | 2014 | https://conductscience.org/library/papers/24332512 | PubMed |
| 8 | 24634660 | Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. | Front Physiol | 2014 | https://conductscience.org/library/papers/24634660 | PubMed |
| 9 | 31187532 | Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease. | Hematol Oncol | 2019 | https://conductscience.org/library/papers/31187532 | PubMed |
| 10 | 17908969 | A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17908969 | PubMed |
| 11 | 22740445 | Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. | Blood | 2012 | https://conductscience.org/library/papers/22740445 | PubMed |
| 12 | 24727328 | Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/24727328 | PubMed |
| 13 | 18086798 | High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18086798 | PubMed |
| 14 | 19636063 | A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. | Blood | 2009 | https://conductscience.org/library/papers/19636063 | PubMed |
| 15 | 7727781 | Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. | Blood | 1995 | https://conductscience.org/library/papers/7727781 | PubMed |
| 16 | 34209703 | Macrophage Polarization States in the Tumor Microenvironment. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34209703 | PubMed |
| 17 | 28977875 | Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma. | Oncotarget | 2017 | https://conductscience.org/library/papers/28977875 | PubMed |
| 18 | 27451390 | Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27451390 | PubMed |
| 19 | 31481504 | A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31481504 | PubMed |
| 20 | 30380386 | CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30380386 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42884057 | Intrafollicular PAI-1 Expression Is Associated with Absence of Histological Transformation During Long-Term Follow-Up in Follicular Lymphoma. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42884057 | PubMed |
| 42046736 | Advancements in Nanomedicine for Precision Management of Lymphoma: Mechanisms, Diagnostics, and Therapeutic Strategies. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42046736 | PubMed |
| 41227317 | Sequencing Cellular Therapies in the Management of Follicular Lymphoma. | Cells | 2025 | https://conductscience.org/library/papers/41227317 | PubMed |
| 40360644 | Identification of the histologic transformation of follicular lymphoma using super-resolution microcirculation imaging. | Sci Rep | 2025 | https://conductscience.org/library/papers/40360644 | PubMed |
| 40015744 | Comprehensive biomarker profiles in hematological malignancies: improving diagnosis, prognosis, and treatment. | Biomark Med | 2025 | https://conductscience.org/library/papers/40015744 | PubMed |
| 39085126 | Mechanisms of lymphoma-stromal interactions focusing on tumor-associated macrophages, fibroblastic reticular cells, and follicular dendritic cells. | J Clin Exp Hematop | 2024 | https://conductscience.org/library/papers/39085126 | PubMed |
| 38115544 | Glucose metabolism in B cell malignancies: a focus on glycolysis branching pathways. | Mol Oncol | 2024 | https://conductscience.org/library/papers/38115544 | PubMed |
| 37681500 | Azurocidin 1 inhibits the aberrant proliferation of triple‑negative breast cancer through the regulation of pyroptosis. | Oncol Rep | 2023 | https://conductscience.org/library/papers/37681500 | PubMed |
Genes95
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35565286
GET https://conductscience.org/api/papers/v1/35565286/references?page=2